We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Enhanced Immunochemistry Analyzers Offer Workstation Consolidation and Efficiency

By LabMedica International staff writers
Posted on 09 Sep 2010
A family of immunochemistry analyzers offers enhanced automation, workstation consolidation, high efficiency, and labor savings for laboratories of all sizes.

The features of the new immunochemistry analyzers, dubbed Architectplus, include more comprehensive and user-friendly software; a smaller size to help reduce space requirements; improvements to streamline operations and reduce interruptions; new video instructions to help with routine maintenance; and an attractive exterior design and styling.

A product of Abbott (Abbott Park, IL, USA), existing Architect systems can be upgraded to Architectplus onsite. The analyzers have an extensive menu of more than 170 assays. Laboratories will be able to reduce labor, optimize throughput, and enhance overall productivity, while standardizing data management processes and optimizing inventory control. The new features will minimize training, and reduce inventory costs and sample contamination potential, resulting in improved performance and outcomes for laboratories, physicians, and patients.

Two new assays recently added were the HE4 for early detection and monitoring of ovarian cancer and the human immunodeficiency virus (HIV) antigen/antibody Combo Assay to identify early HIV infections. Additionally, Abbott has more than a dozen novel biomarkers in development, and several are expected to be introduced within months of the introduction of the analyzers.


"According to the Health and Human Services Administration on Aging, one in five Americans will be age 65 and older in 20 years. It's well documented that older people are the largest consumers of health care services, and the huge growth in this age group will likely generate significant new demand for routine lab tests and follow-up testing for diabetes, cancer and other conditions," said Brian Blaser, senior vice president, diagnostics, Abbott. "Already stressed with finding ways to deal with diminishing resources and a serious shortage of trained staff, laboratories are turning to diagnostics manufacturers for technologies and capabilities they need to operate effectively and survive in this environment."

Architectplus was showcased for the first time at the annual American Association for Clinical Chemistry Lab Expo, which was held in Anaheim, (CA, USA) from July 25-29, 2010.

Related Links:

Abbott
American Association for Clinical Chemistry




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Liquid Based Cytology Production Machine
LBP-4032

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients